| Ytd | -67.51% | |
| 1y | -47.87% |
| Open | 3.69 | Prev Close | 3.68 | Low | 3.66 | High | 3.73 | Mkt Cap | 199.13M |
| Vol | 141.23K | Avg Vol | 2.46M | EPS | -1.15 | P/E | -3.20 | Forward P/E | -3.84 |
| Beta | 3.01 | Short Ratio | 7.67 | Inst. Own | 89.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-27 | 50-d Avg | 4.59 | 200-d Avg | 8.18 | 1yr Est | 5.29 |
FULC News
New York, New York--(Newsfile Corp. - July 20, 2026) - Kaplan Fox & Kilsheimer LLP is investigating
New York, New York--(Newsfile Corp. - July 17, 2026) - Kaplan Fox & Kilsheimer LLP is investigating
Fulcrum Therapeutics, Inc. stock lost roughly half its value after the FDA flagged class-wide safety
The heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically
Fulcrum Therapeutics, Inc. stock lost roughly half its value in a single session after the company d
NEW YORK--(BUSINESS WIRE)--Shareholders of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) saw the stock p
Fulcrum Therapeutics Inc. (NASDAQ:FULC) shares are up on Thursday as the company faces significant c
Fulcrum Therapeutics stock sinks 51% after ending pociredir development in SCD due to FDA cancer-ris
SEC filings reflected insider equity holdings and awards totaling more than 264,000 shares NEW YORK,
Fulcrum Therapeutics, Inc. guided investors toward a Phase III future for pociredir while a $25.1 mi
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Fulcrum T
ATLANTA, June 02, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Fulcrum The
Wall Street analysts change ratings for top stocks: CRWD price target raised, FULC target lowered, H
Shares of Fulcrum Therapeutics plunged 50% in premarket trading on Tuesday after the company said it
HPE stock jumps 26.55% after reporting strong revenue growth. Top gainers are DXST, MRVL and more. T
Fulcrum Therapeutics stock plunged after the company discontinued its lead sickle cell disease drug
Fulcrum Therapeutics said on Monday it would stop developing its experimental sickle-cell disease dr
― Decision follows FDA feedback regarding the implications of the secondary malignancies observed wi
The heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically
CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a cli
Fulcrum Therapeutics, Inc. (FULC) Q1 2026 Earnings Call Transcript
― Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (H
U.S. stock futures lower on Thursday with Applied Digital Corp. (APLD) falling sharply in pre-market
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen
U.S. stock futures up, Dow gains 150 points. Avis Budget Group (CAR) shares fall 9.6% in pre-market.
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is expected to report earnings for
Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly e
Before 10 a.m. ET on Thursday, 91 companies hit new 52-week highs.